Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE.
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE vs TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative that antagonizes histamine H1 receptors, reducing allergic symptoms; it also has anticholinergic, antiemetic, and sedative effects. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia and antitussive effects by central mechanisms.
Trimethobenzamide is a centrally acting antiemetic that inhibits the chemoreceptor trigger zone (CTZ) in the medulla oblongata by suppressing emetic stimuli. Its exact mechanism is not fully understood but may involve antagonism of dopamine D2 receptors and possibly serotonin 5-HT3 receptors.
Adults: 5 mL (containing promethazine 6.25 mg and codeine 10 mg) orally every 4-6 hours as needed; maximum 30 mL per day.
300 mg orally or intramuscularly 3 to 4 times daily as needed for nausea and vomiting.
None Documented
None Documented
Promethazine: 10-19 hours (range 5-30h); Codeine: 2.5-4 hours (rapidly metabolized); Clinical context: sustained antitussive effect from codeine despite short half-life. Half-life of promethazine extends with hepatic impairment.
Terminal elimination half-life approximately 7-9 hours in adults; prolonged in renal impairment (up to 20-30 hours).
Renal: Codeine and metabolites ~90% (free and conjugated), Promethazine and metabolites primarily renal; minor biliary/fecal (<5% for codeine, ~6% for promethazine).
Primarily renal (50-70% as unchanged drug and metabolites) and biliary (~20-30%); less than 5% fecal.
Category A/B
Category C
Antihistamine / Antiemetic
Antiemetic